The novel combination of afoxolaner plus milbemycin oxime, NexGard Spectra®, was evaluated against the migrating Dirofilaria immitis larvae in beagle dogs in two negative control, blinded laboratory studies. In each study, dogs were randomly allocated to an untreated control and a treated group of 10 dogs each. In each study, dogs were inoculated with third stage D. immitis larvae by subcutaneous injection (50 larvae in the first, 100 larvae in the second study). The larvae had grown into L3 stage in mosquitoes fed on blood obtained in the field from naturally infected dogs in Italy (Lombardy for the first, Sardinia for the second study). Thirty-one days after inoculation, each dog in the treated group was orally treated with NexGard Spectra® dosed as close as possible to the minimum effective dose (2.5 mg/kg Afoxolaner + 0.5 mg/kg milbemycin oxime). The control group remained untreated. All dogs were humanely euthanized and examined for adult D. immitis 146 or 147 days after inoculation. In the first study, seven of the ten untreated dogs were infected, harboring 1 to 5 adult D. immitis. In the second study, the ten untreated dogs were positive and harbored 22 to 46 adult D. immitis. In both studies all treated dogs remained free of heartworm infection as no D. immitis was recovered, demonstrating that the novel combination of afoxolaner plus milbemycin oxime was 100% effective in preventing heartworm disease in dogs.

Efficacy of oral afoxolaner plus milbemycin oxime chewable (NexGard Spectra®, Merial) to prevent heartworm disease in dogs after inoculation with third stage larvae of Dirofilaria immitis / Tielemans, Eric; Lebon, Wilfried; Dumont, Pascal; Genchi, Marco; Jeannin, Philippe; Larsen, Diane. - (2015). (Intervento presentato al convegno 25th International Conference of the World Association for the Advancement of Veterinary Parasitology tenutosi a Liverpool (UK) nel 16-20 August, 2015).

Efficacy of oral afoxolaner plus milbemycin oxime chewable (NexGard Spectra®, Merial) to prevent heartworm disease in dogs after inoculation with third stage larvae of Dirofilaria immitis

GENCHI, Marco;
2015-01-01

Abstract

The novel combination of afoxolaner plus milbemycin oxime, NexGard Spectra®, was evaluated against the migrating Dirofilaria immitis larvae in beagle dogs in two negative control, blinded laboratory studies. In each study, dogs were randomly allocated to an untreated control and a treated group of 10 dogs each. In each study, dogs were inoculated with third stage D. immitis larvae by subcutaneous injection (50 larvae in the first, 100 larvae in the second study). The larvae had grown into L3 stage in mosquitoes fed on blood obtained in the field from naturally infected dogs in Italy (Lombardy for the first, Sardinia for the second study). Thirty-one days after inoculation, each dog in the treated group was orally treated with NexGard Spectra® dosed as close as possible to the minimum effective dose (2.5 mg/kg Afoxolaner + 0.5 mg/kg milbemycin oxime). The control group remained untreated. All dogs were humanely euthanized and examined for adult D. immitis 146 or 147 days after inoculation. In the first study, seven of the ten untreated dogs were infected, harboring 1 to 5 adult D. immitis. In the second study, the ten untreated dogs were positive and harbored 22 to 46 adult D. immitis. In both studies all treated dogs remained free of heartworm infection as no D. immitis was recovered, demonstrating that the novel combination of afoxolaner plus milbemycin oxime was 100% effective in preventing heartworm disease in dogs.
2015
Efficacy of oral afoxolaner plus milbemycin oxime chewable (NexGard Spectra®, Merial) to prevent heartworm disease in dogs after inoculation with third stage larvae of Dirofilaria immitis / Tielemans, Eric; Lebon, Wilfried; Dumont, Pascal; Genchi, Marco; Jeannin, Philippe; Larsen, Diane. - (2015). (Intervento presentato al convegno 25th International Conference of the World Association for the Advancement of Veterinary Parasitology tenutosi a Liverpool (UK) nel 16-20 August, 2015).
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2802382
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact